Research ArticleOpen AccessGoogle Scholar indexed
Monte Carlo Analysis of Different Administration Regiments for Isavuconazole against <i>Candida spp.</i> and <i>Aspergillus spp.</i>
Department of Clinic Pharmacy, Affiliated of Chengde Medical College, Chengde, China
Department of Oncology Department, The Affiliated Hospital of Chengde Medical College, Chengde, China
Department of Clinic Pharmacy, Affiliated of Chengde Medical College, Chengde, China
- 1 Department of Clinic Pharmacy, Affiliated of Chengde Medical College, Chengde, China
- 2 Department of Oncology Department, The Affiliated Hospital of Chengde Medical College, Chengde, China
- 3 Department of Clinic Pharmacy, Affiliated of Chengde Medical College, Chengde, China
Pharmacology & Pharmacy·Volume 12 (2021)·Pages 311–318·Published 6 December 2021·DOI10.4236/pp.2021.1212026
Copy link · social · email
Abstract
In our study, we aimed to optimize the dosage regimen of Isavuconazole against Candida spp. and Aspergillus spp. by Mo n te Carlo simulation (MSC). Pharmacokinetic parameters and microbiological data of Isavuconazole were collected. Then we used MSC to simulate 10,000 patients analyzed by Crystal Ball to calculate probability of target attainment (PTA) and cumulative fraction of response (CFR). With dosages of 100 mg, 200 mg, and 400 mg in oral group and dosages of 100 mg, and 200 mg in intravenous administration, all have different degree s of antifungal effect. But when the dosage regimen was 50 mg IV, the therapeutic effect of Isavuconazole against Aspergillus spp. and Candida spp. were not good.
KeywordsMonte Carlo Simulation (MSC)Isavuconazole<i>Candida spp.</i><i>Aspergillus spp.</i>
- Kyle, J.W. (2018) A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. European Journal of Drug Metabolism and Pharmacokinetics, 43, 281-290. https://doi.org/10.1007/s13318-017-0445-7
- Donnelley, M., Zhu, E. and Thomopson, G. (2016) Isavuconazole in the Treatment of Invasive Aspergillosis and Mucormycosis Infections. Infection and Drug Resistance, 9, 79-86. https://doi.org/10.2147/IDR.S81416
- Miceli, M.H. and Kauffman, C.A. (2015) Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clinical Infectious Diseases, 61, 1558-1565. https://doi.org/10.1093/cid/civ571
- Thompson III, G.R. and Wiederhold, N.P. (2010) Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole. Mycopathologia, 170, 291-313. https://doi.org/10.1007/s11046-010-9324-3
- Espinel-Ingroff, A., Chowdhary, A., Gonzalez, G.M., et al. (2015) Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for the Cryptococcus Neoformans-Cryptococcus Gattii Species Complex Using the CLSI M27-A3 Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 59, 666-668. https://doi.org/10.1128/AAC.04055-14
- Pfaller, M.A., Rhomberg, P.R., Messer, S.A., Jones, R.N. and Castanheira, M. (2015) Isavuconazole, Micafungin, and 8 Comparator Antifungal Agents’ Susceptibility Profiles for Common and Uncommon Opportunistic Fungi Collected in 2013: Temporal Analysis of Antifungal Drug Resistance Using CLSI Species-Specific Clinical Breakpoints and Proposed Epidemiological Cutoff Values. Diagnostic Microbiology and Infectious Disease, 82, 303-313. https://doi.org/10.1016/j.diagmicrobio.2015.04.008
- Denis, J., Ledoux, M.-P., Nivoix, Y., et al. (2018) Isavuconazole: A New Broad-Spectrum Azole. Part 1: In Vitro Activity. Journal de Mycologie Médicale, 28, 8-14. https://doi.org/10.1016/j.mycmed.2018.02.005
- Schmitt-Hoffmann, A., Roos, B., Heep, M., et al. (2006) Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 50, 279-285. https://doi.org/10.1128/AAC.50.1.279-285.2006
- Rybak, J.M., Marx, K.R., Nishimoto, A.T., et al. (2016) Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 35, 1037-1051. https://doi.org/10.1002/phar.1652